Filtered By:
Specialty: Cardiology
Drug: Insulin

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 191 results found since Jan 2013.

Randomized placebo controlled trial evaluating the safety and efficacy of single low dose intracoronary insulin like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI)
Conclusion In this pilot trial, low dose IGF1, given after optimal mechanical reperfusion in STEMI, is safe but does not improve LVEF. However, there is a signal for a dose dependent benefit on post MI remodeling that may warrant further study.
Source: American Heart Journal - April 3, 2018 Category: Cardiology Source Type: research

Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women Original Articles
Conclusions: Circulating plasma BCAAs were positively associated with incident CVD in women. Impaired BCAA metabolism may capture the long-term risk of the common cause underlying T2D and CVD.
Source: Circulation: Cardiovascular Genetics - March 23, 2018 Category: Cardiology Authors: Tobias, D. K., Lawler, P. R., Harada, P. H., Demler, O. V., Ridker, P. M., Manson, J. E., Cheng, S., Mora, S. Tags: Biomarkers, Cardiovascular Disease, Diabetes, Type 2, Epidemiology, Women Original Articles Source Type: research

Glycemic variability, but not HbA1c, is associated with high SYNTAX scores at the acute phase of myocardial infarction (AMI) in diabetic patients treated with insulin infusion
Conclusion GV was mainly associated with diabetes-related factors, and was independently associated with a high SYNTAX score. Our findings suggest that assessment of blood GV could contribute to the identification of high-risk diabetics and become a therapeutic target in primary and secondary prevention.
Source: Archives of Cardiovascular Diseases Supplements - January 5, 2018 Category: Cardiology Source Type: research

Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study
Conclusion Based on a large UK cohort in routine clinical practice, adding a GLP-1RA to insulin therapy is associated with a reduction in risk of composite CV events and all-cause mortality but a nonsignificant higher risk of hospitalization for heart failure in overweight patients with T2D.
Source: American Heart Journal - December 1, 2017 Category: Cardiology Source Type: research

Impact of hyperhomocysteinemia on insulin resistance in patients with H-type hypertension.
CONCLUSIONS: HHcy obviously exacerbate insulin resistance, especially in H-type HT patients. HHcy and HT have a multiplicative effect on metabolic dysfunction, which may help to interpret why these patients are suffering a high risk of cardiovascular disease and stroke. PMID: 29172743 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Hypertension - November 27, 2017 Category: Cardiology Authors: Zhang Y, Wang G, Liu J, Xu Y Tags: Clin Exp Hypertens Source Type: research

A High-Fat and High-Cholesterol Diet Induces Cardiac Fibrosis, Vascular Endothelial, and Left Ventricular Diastolic Dysfunction in SHRSP5/Dmcr Rats.
CONCLUSIONS: SHRSP5/Dmcr rats may be a suitable animal model for elucidating the organ interaction between NASH and cardiac or vascular dysfunction. PMID: 29162773 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - November 23, 2017 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Pioglitazone Prevents Stroke in Patients with a Recent TIA or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial.
Conclusions -Pioglitazone was effective for secondary prevention of ischemic stroke in non-diabetic patients with insulin resistance. Clinical Trial Registration -URL: http://www.clinicaltrials.gov. Unique identifier: NCT00091949. PMID: 29084736 [PubMed - as supplied by publisher]
Source: Circulation - October 30, 2017 Category: Cardiology Authors: Yaghi S, Furie KL, Viscoli CM, Kamel H, Gorman M, Dearborn J, Young LH, Inzucchi SE, Lovejoy AM, Kasner SE, Conwit R, Kernan WN, IRIS Trial Investigators Tags: Circulation Source Type: research

Response by Young et al to Letters Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
PMID: 29038213 [PubMed - in process]
Source: Circulation - October 17, 2017 Category: Cardiology Authors: Young LH, Viscoli CM, Inzucchi SE, Kernan WN Tags: Circulation Source Type: research

Letter by Jin-Shan and Xue-Bin Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
PMID: 29038212 [PubMed - in process]
Source: Circulation - October 17, 2017 Category: Cardiology Authors: Jin-Shan H, Xue-Bin L Tags: Circulation Source Type: research

Letter by Musso et al Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
PMID: 29038211 [PubMed - in process]
Source: Circulation - October 17, 2017 Category: Cardiology Authors: Musso G, Cassader M, Gambino R Tags: Circulation Source Type: research

Effect of adding GLP-1RA on mortality, cardiovascular events and metabolic outcomes among insulin-treated patients with Type 2 Diabetes: A Large Retrospective UK Cohort Study
Conclusion Based on a large UK cohort in routine clinical practice, adding a GLP-1RA to insulin therapy is associated with a reduction in risk of composite CV events and all-cause mortality, but non-significant higher risk of hospitalisation for heart failure in overweight patients with Type 2 diabetes.
Source: American Heart Journal - October 10, 2017 Category: Cardiology Source Type: research

GLP-1 receptor agonists: An example of the challenge for animal models to predict plaque instability/rupture and cardiovascular outcomes
Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by hyperglycaemia and insulin resistance. Diabetes mellitus is well-established as a major risk factor for the development of cardiovascular disease (CVD). A collaborative meta-analysis of 102 prospective studies revealed that people with diabetes are exposed to two-fold excess risk for coronary heart disease and stroke after adjustment for lipid profiles and inflammatory markers [1]. Moreover, prevention of cardiovascular complications is regularly integrated in the regime of medical care in diabetic patients, as these patients have a similar ri...
Source: Atherosclerosis - August 18, 2017 Category: Cardiology Authors: Ya-Lan Ying, Yung-Chih Chen, Karin Jandeleit-Dahm, Karlheinz Peter Tags: Editorial Source Type: research

Clinical case of hyperlipidemia type IV in a man with diabetes, myocardial infarction and stroke
Aim: Hypercholesterolemia is one of the main risk factors of atherosclerosis development. Lipid disorders occur as a result of some genetic abnormalities or secondary to underlying disease, for example, diabetes mellitus. Insulin resistance in such patient is often the reason of hypertriglyceridemia and low serum high-density lipoprotein cholesterol concentrations. Hypertriglyceridemia is the most common lipid abnormality in young patients with myocardial infarction.
Source: Atherosclerosis - August 1, 2017 Category: Cardiology Authors: Olga Baturina, Olga Mironova Source Type: research

Pioglitazone and cardiovascular risk reduction: time for a second look?
Insulin resistance, a fundamental pathophysiological abnormality in patients with type 2 diabetes, is associated with increased cardiovascular (CV) disease risk. In diabetes management, the macrovascular impact of antihyperglycemic agents that do not improve insulin sensitivity has generally been disappointing. In contrast, glucose-lowering drugs that work as insulin sensitizing agents have been postulated to reduce CV complications. The data to support this hypothesis have, however, been inconsistent. The impact of thiazolidinediones on macrovascular events is of particular interest. In this review, we discuss the results...
Source: Cardiovascular Endocrinology - May 12, 2017 Category: Cardiology Tags: Review articles Source Type: research

Abstract 013: Using the Diabetes Collaborative Registry (DCR) to Estimate the Potential Real-world Impact of the Iris Trial on Improving Outcomes in Patients With Cerebrovascular Disease Session Title: Poster Session I
Conclusion: In a large US-based outpatient registry, we found that 12% of outpatients with prediabetes or diet-controlled T2D met the main eligibility criteria for IRIS, partly due to the narrow inclusion criteria of the trial but also likely reflective of a general paucity of screening for prediabetes and insulin resistance in this cohort. Pioglitazone was rarely used in these patients but could have a substantial impact on CV outcomes in these eligible patients. The population impact could be even greater if the CV benefit of pioglitazone can be demonstrated in patients with cerebrovascular disease and overt T2D or even ...
Source: Circulation: Cardiovascular Quality and Outcomes - March 31, 2017 Category: Cardiology Authors: Arnold, S. V., Inzucchi, S. E., Tang, F., McGuire, D. K., Mehta, S. N., Maddox, T. M., Goyal, A., Sperling, L. S., Einhorn, D., Wong, N. D., Kosiborod, M. Tags: Session Title: Poster Session I Source Type: research